Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia
Launched by MARC KIVINIEMI · Jul 16, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The intervention trial will be a community-based, three-arm cluster randomized controlled trial. The three arms are: (1) multilevel invention (vaccine communication campaign + community-level structural intervention),(2) health communications only intervention, and (3) control/standard of care. Randomization will take place at the county level. The 15 participating counties will first be matched into blocks of three, with each block being matched as closely as possible on recent county influenza vaccination rates. After matching, the three counties within each matched block will be randomly...
Gender
ALL
Eligibility criteria
- • Up to 2,250 participants will take part in the study --- approximately 150 residents in each of the 15 participating Appalachian Kentucky Counties. In each of the fifteen counties, the investigators will collect survey data from 150 adults who are served by Homeplace, a medical and social services organization run by the UK Center for Excellence in Rural Health, which provides services in each of the 15 partner counties. Homeplace provides services to adults who are medically underserved and typically at 100-133% of the federal poverty level, primarily through service delivery by trained local Community Health Workers (CHWs). CHWs will recruit participants and collect the survey data from the identified individuals. Importantly, the criteria for qualification for Homeplace services are equivalent across the 15 counties, providing equivalence of sample across counties. A random sample of 150 individuals per county will be drawn from the Homeplace client database for that county. Gender, ethnic background, and health status will roughly mirror that of the demographics of the county.
- Inclusion Criteria:
- • 1. Must be a current Homeplace client
- • 2. Live in one of the 15 selected study counties
- • 3. Over the age of 18
- • 4. Have the ability to complete the survey in English
- Exclusion Criteria:
- • 1. Not a current Homeplace client
- • 2. Primary residence is not in one of the 15 study counties
- • 3. Not within the ages of 18-99 years old
- • 4. English is not your primary language
About Marc Kiviniemi
Marc Kiviniemi is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical standards, the organization promotes the development and execution of clinical trials that address unmet medical needs across various therapeutic areas. Leveraging a team of experienced professionals, Marc Kiviniemi fosters collaboration with healthcare providers, regulatory bodies, and research institutions to ensure the highest quality of research and compliance with industry regulations. Their mission is to contribute to the advancement of healthcare by facilitating the discovery and development of safe and effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hazard, Kentucky, United States
Patients applied
Trial Officials
Marc T. Kiviniemi, PhD
Principal Investigator
University of Kentucky
Kathryn M. Cardarelli, PhD, MPH
Principal Investigator
University of Louisville
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported